Setting a new standard in biosimilars.
Latest news
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
- Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
- Alvotech and OACB Announce Extraordinary General Meeting to Approve Business Combination
Who we are?
We are passionate people, working to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.
Our approach
We believe that a vertically integrated approach, from cell line development through fill and finish manufacturing, gives us the control, scale and speed needed to achieve our mission. We maintain our singular focus on what we do best while relying on the deep expertise of our partners for commercialization.
Our Pipeline
We are committed to developing and manufacturing high-quality, cost-competitive biosimilars. We continually evaluate additional pipeline opportunities to bring a strategic and robust selection of biologic medicines to patients around the world.
Latest news
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
Alvotech and OACB Announce Extraordinary General Meeting to Approve Business Combination
Join our team
Here at Alvotech, we want our employees to feel inspired in their careers and challenged by interesting and meaningful work. That’s why we are proud of our purpose-driven culture. We are always interested in speaking to passionate, experienced individuals. Are you ready to join our growing team?